Showkat Ahmad Bhat | Cancer Biology | Best Researcher Award

Posted on by ScienceFather

Dr.Showkat Ahmad Bhat | Cancer Biology | Best Researcher Award

Associate professor, Govt. Medical College Handwara 

Dr. Showkat Ahmad Bhat is an Associate Professor in the Department of Biochemistry at Govt. Medical College (GMC) Handwara & Associated Hospitals, Jammu & Kashmir, India. With extensive experience in clinical biochemistry and molecular biology, his research focuses on cancer biology, proteomics, and epigenetics. He has held various academic and administrative roles in reputed institutions, including GMC Srinagar, GMC Doda, and Al-Falah School of Medical Science & Research Centre. Dr. Bhat has actively contributed to scientific research through multiple funded projects and has received prestigious fellowships from ICMR and CSIR. His expertise extends to communicable diseases, parasitic resistance, and biochemical laboratory techniques. A passionate educator and researcher, he has presented at national and international conferences, winning awards for his contributions to cancer diagnostics and molecular research. His work is dedicated to advancing medical science through innovative biochemical methodologies and fostering academic excellence in medical education.

Profile

Scholar

 Education 

Ph.D. in Biochemistry – BU Rajasthan, Sikar Road, Ajmer M.Sc. in Clinical Biochemistry – University of Kashmir Six-month Internship – Sher-i-Kashmir Institute of Medical Sciences, Soura, Srinagar B.Sc. in Medical Sciences – S.P. College, Srinagar, Kashmir University  Computer Diploma – NCPUL and DOEACC, Ministry of HRD & IT, Centre Budgam 12th Class (Medical Stream) – Jammu & Kashmir Board of School Education, Srinagar

 Experience 

Associate Professor (2023–Present) – GMC Handwara & Associated Hospitals, Jammu & Kashmir Assistant Professor (2023) – GMC Handwara & Associated Hospitals, Jammu & Kashmir Assistant Professor (2022–2023) – Al-Falah School of Medical Science & Research Centre, Haryana Assistant Professor (2019–2022) – GMC Doda & Associated Hospitals, Jammu & Kashmir Demonstrator/Tutor (2017–2019) – GMC Srinagar, Jammu & Kashmir Research Fellow (2008–2017) – Various ICMR and DST-funded projects on cancer biomarkers, epigenetics, and molecular diagnostics Administrative Roles (2018–Present) – Curriculum Coordinator, Lab Coordinator, IT & Biometric In-Charge, Academic Section Head, Hostel Warden

Awards & Honors 

ICMR Grant (2019) – Workshop on Biochemical Laboratory Techniques CSIR Research Associateship (2017) – RA-3 Scheme Fello DST Travel Grant (2015, 2014, 2013) – Attended international and national conferences, including the 101st & 100th Indian Science Congress Best Oral Presentation Award (2015) – National Conference BIOCME on Advances in Biochemical & Molecular Diagnostics RCR Ross Prize Entrant (2013) – Methylation Status Study in Colorectal Cancer (UK Conference) ICMR Senior Research Fellowship (2013) – Molecular Cancer Diagnostics Various Prestigious Fellowships & Grants – Recognized for outstanding contributions to cancer biomarker research and molecular biochemistry

 Research Focus 

Cancer Biology – Early diagnostic markers, epigenetic modifications, and molecular profiling in gastric and colorectal cancer  Clinical Biochemistry – Biomarkers in disease progression and metabolic disorders Proteomics & Molecular Biology – Protein expression analysis for disease characterization Epigenetics – DNA methylation and gene regulation in carcinogenesis Communicable Diseases – Molecular mechanisms of infectious disease resistance Parasitic Resistance – Studying biochemical adaptations in parasitic infections Biochemical Diagnostics – Development of novel techniques for improved disease detection and treatment strategies

Conclusion

Dr. Showkat Ahmad Bhat’s extensive research experience, significant grants and fellowships, high-quality publications, and innovative projects make him a strong candidate for the Best Researcher Award. Addressing the identified areas for improvement could further enhance his candidacy and contribute to his professional growth.

Puplication

  • Bilal Ahmad, SB., Rehman, M.U., Amin, I., Arif, A., Rasool, S., et al. (2015). “A Review on Pharmacological Properties of Zingerone (4-(4-Hydroxy-3-methoxyphenyl)-2-butanone).” The Scientific World Journal, 1-6. (281 citations)

 

  • Bhat, S.A., Hassan, T., Majid, S. (2019). “Heavy metal toxicity and their harmful effects on living organisms–a review.” International Journal of Medical Science And Diagnosis Research, 3(1), 106-122. (100 citations)

 

  • Dar, RASNAG M.A., Ahmad, S.M., Bhat, S.A., Ahmed, R., Urwat, U., Mumtaz, P.T., et al. (2017). “Salmonella typhimurium in poultry: a review.” World’s Poultry Science Journal, 73(2), 345-3. (90 citations)

 

  • Bashir, A.H., Bhat, S.A., Majid, S., Hamid, R., et al. (2020). “Role of inflammatory mediators (TNF-α, IL-6, CRP), biochemical and hematological parameters in type 2 diabetes mellitus patients of Kashmir, India.” Medical Journal of the Islamic Republic of Iran (MJIRI), 34(5), 1-6. (74 citations)

 

  • Reshi, A.A., Husain, I., Bhat, S.A., Rehman, M.U., Razak, R., et al. (2015). “Bovine mastitis as an evolving disease and its impact on the dairy industry.” IJCRR, 7(5), 48-55. (66 citations)

 

  • Rehman, M.U., Rashid, S.M., Rasool, S., Shakeel, S., Ahmad, B., Ahmad, S.B., et al. (2019). “Zingerone (4-(4-hydroxy-3-methylphenyl) butan-2-one) ameliorates renal function via controlling oxidative burst and inflammation in experimental diabetic nephropathy.” Archives of Physiology and Biochemistry, 125(3), 201-209. (58 citations)

 

  • Bhat, S.A., Mir, M.U.R., Qadir, S., Mehraj, I., et al. (2012). “Prevalence of gastro-intestinal parasitic infections in Sheep of Kashmir valley of India.” Veterinary World, 5(11), 667-671. (48 citations)

 

  • Bhat, S.A., Saravanan, P., Hosamani, M., Basagoudanavar, S.H., et al. (2013). “Novel immunogenic baculovirus expressed virus-like particles of foot-and-mouth disease (FMD) virus protect guinea pigs against challenge.” Research in Veterinary Science, 95(3), 1217-1223. (45 citations)

 

  • Ahmad, S.B., Rehman, M.U., Fatima, B., Ahmad, B., et al. (2017). “Antifibrotic effects of D-limonene (5(1-methyl-4-[1-methylethenyl]) cyclohexane) in CCl-induced liver toxicity in Wistar rats.” Environmental Toxicology, 1-9. (39 citations)

 

  • Malik, M.A., Bhat, S.A., Fatima, B., Ahmad, S.B., Sidiqui, S., Shrivastava, P. (2016). “Rheum emodi as a valuable medicinal plant.” International Journal of General Medicine and Pharmacy, 5(4), 35-44. (32 citations)

 

  • Bhat, S.A., Majid, S., Wani, H.A., Rashid, S. (2019). “Diagnostic utility of epigenetics in breast cancer–a review.” Cancer Treatment and Research Communications, 19, 100125. (30 citations)

 

  • Bhat, S.A., Mir, M.R., Majid, S., Reshi, A.A., Husain, I., Hassan, T., Ahmad, H. (2019). “Serum lipid profile of breast cancer patients in Kashmir.” (Journal details not provided). (Citation count not mentioned)

 

Merve Keskinkilic | Medical Oncology | Best Researcher Award

Posted on by ScienceFather

Dr. Merve Keskinkilic | Medical Oncology | Best Researcher Award

Medical Oncologist, Izmir Democracy University Buca Seyfi Demirsoy Training and Research Hospital Turkey

Merve Keskinkılıç is a dedicated Medical Oncologist at Burdur State Hospital with a strong academic background in Internal Medicine and Medical Oncology. She earned her M.D. from Dokuz Eylul University Faculty of Medicine and completed her Medical Oncology Fellowship at the same institution. Dr. Keskinkılıç has extensive clinical experience, having served as a Research Fellow at Emory University, USA. Fluent in English (C1 Advanced) and proficient in German (Elementary), she actively participates in international oncology research. Her expertise includes clinical trials, cancer treatment strategies, and translational oncology research, contributing significantly to advancements in the field.

Publication Profile

Scopus

Scholar

🎓 Education

Dr. Keskinkılıç completed her high school education at Balıkesir Science High School (2004-2008) before pursuing medicine at Dokuz Eylul University (2008-2014). She participated in an Oncology Exchange Program at Mansoura University, Egypt (2010). She later obtained an Associate Degree in Healthcare Management from Anadolu University (2014-2017). Her residency in Internal Medicine was completed at Celal Bayar University (2015-2016) and Dokuz Eylul University (2016-2019). She pursued a Medical Oncology Fellowship at Dokuz Eylul University (2019-2024) and is currently undertaking a PhD in Basic Oncology at Dokuz Eylul University Oncology Institute (since 2022). She also worked as a Research Fellow at Emory University, USA (2023).

💼 Experience

Dr. Keskinkılıç began her career as a General Practitioner at Balıkesir Susurluk State Hospital (2014-2015) before becoming a Research Assistant in Internal Medicine at Celal Bayar University (2015-2016) and later at Dokuz Eylul University (2016-2019). She served as a Specialist Doctor at Bitlis Mutki State Hospital (2019) and as a Fellow in Medical Oncology at Dokuz Eylul University (2019-2024). Currently, she is a Medical Oncologist at Burdur Public Hospital (2024-2025) and will join Izmir Democracy University Buca Seyfi Demirsoy Training and Research Hospital in 2025.

🏆 Awards & Honors

Dr. Keskinkılıç holds several prestigious certifications, including the Turkish Board of Internal Medicine Certificate (2018), Experimental Animal Use Certificate (2019), Oncology Clinical Research Training Certificate (2020), and ESMO Board of Examination Certificate (2023). She has also completed Good Clinical Practices (ICU) and Clinical Research Training and has received certifications in Research Ethics and Clinical Trials. Her contributions to oncology research and education have been recognized through multiple national and international accolades.

🔬 Research Focus

Dr. Keskinkılıç specializes in clinical oncology research, focusing on urothelial, bladder, gastric, prostate, and lung cancers. She is actively involved in multiple clinical trials, serving as a Sub-Investigator in research projects such as THOR (Urothelial Cancer), Niagara (Bladder Cancer), MK3475-859 (Gastric Cancer), Regeneron (Non-Small Cell Lung Cancer), and Radiant 20510 (Prostate Cancer). Her work emphasizes innovative treatment strategies, immunotherapy, and targeted cancer therapies, contributing to the development of advanced oncological treatments. Her internal medicine dissertation evaluated CMV DNA Antigenemia in Allogeneic Bone Marrow Transplant Patients.

Publication Top Notes

  • Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
    • Authors: C. Karacin, B. Oksuzoglu, A. Demirci, M. Keskinkılıç, et al.
    • Journal: BMC Cancer, 2023
    • Citations: 20

 

  • Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
    • Authors: S. Kahraman, E. Erul, M. Seyyar, O. Gumusay, et al.
    • Journal: Future Oncology, 2023
    • Citations: 13

 

  • Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: a multicenter study
    • Authors: H. Ç. Yıldırım, E. Mutlu, E. Chalabiyev, M. Özen, et al.
    • Journal: The Breast, 2022
    • Citations: 13

 

  • The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor-positive breast cancer patients treated with a combination of a CDK4/6 inhibitor and…
    • Authors: E. C. Yildirim, E. Atag, E. Coban, et al.
    • Journal: The Breast, 2023
    • Citations: 12

 

  • Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia
    • Authors: H. C. Yildirim, C. Kapar, B. Koksal, et al.
    • Journal: Journal of Chemotherapy, 2024
    • Citations: 4

 

  • The prognostic indicator in breast cancer treated with CDK4/6 inhibitors: the prognostic nutritional index
    • Authors: M. Keskinkilic, H. S. Semiz, G. Polat, et al.
    • Journal: Future Oncology, 2023
    • Citations: 4

 

  • Antibody-Drug Conjugates in Triple Negative Breast Cancer
    • Authors: M. Keskinkilic, R. Sacks
    • Journal: Clinical Breast Cancer, 2024
    • Citations: 3

 

  • 194P Increased blood creatinine level due to CDK 4/6 inhibitor treatments: single center experience
    • Authors: M. Keskinkılıç, H. S. Semiz, T. Yavuzsen, A. Karaoglu
    • Journal: Annals of Oncology, 2022
    • Citations: 3

 

  • The prognostic nutritional index (PNI): A new biomarker for determining prognosis in metastatic castration-sensitive prostate carcinoma
    • Authors: H. I. Ellez, M. Keskinkilic, et al.
    • Journal: Journal of Clinical Medicine, 2023
    • Citations: 11

 

  • The role of immune checkpoint inhibition in triple-negative breast cancer
    • Authors: K. Tarekegn, M. Keskinkilic, T. J. Kristoff, S. T. Evans, K. Kalinsky
    • Journal: Expert Review of Anticancer Therapy, 2023
    • Citations: 10

 

  • The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer
    • Authors: M. Hizal, B. Bilgin, N. Paksoy, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2023
    • Citations: 5

 

  • CD47 (‘don’t eat me’ signal) expression levels and its relationship with clinicopathologic features in early‐stage prostate carcinoma
    • Authors: H. S. Semiz, Ü. Küçük, E. Kısa, M. Keskinkılıç, et al.
    • Journal: The Prostate, 2022
    • Citations: 5

 

  • A severe case of levothyroxine intoxication successfully treated in intensive care unit
    • Authors: Y. Savran, T. Mengi, M. Keskinkilic
    • Journal: Journal of Acute Disease, 2018
    • Citations: 11

 

 

Ashwani Patil | Cancer Biology | Best Scholar Award

Posted on by ScienceFather

Dr. Ashwani Patil | Cancer Biology | Best Scholar Award

Assistant Professor, Dr. D. Y. Patil Institute of Pharmaceutical Sciences & Research India

Dr. Ashwani Patil is a passionate pharmacologist specializing in neurological disorders and cancer research. He completed his Ph.D. in Pharmacology from the Institute of Chemical Technology (ICT), Mumbai, with a focus on preclinical drug development. His research at Bhabha Atomic Research Centre and NIRRH Mumbai deepened his expertise in molecular mechanisms underlying complex diseases. With hands-on experience in animal handling, molecular techniques, and pharmacological testing, he has contributed significantly to understanding disease pathology and potential therapeutic targets for cancer and neurological disorders.

Professional Profile 

Scopus

Scholar

🎓Education

Ph.D. in Pharmaceutical Tech. (Pharmacology), Institute Of Chemical Technology, Mumbai (2024). M. Pharmacy (Pharmacology), R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur (2018). Bachelor of Pharmacy, A.R.A College of Pharmacy, Dhule (2016)

💼Experience

Junior Research Fellow, R.C. Patel Institute of Pharmaceutical Education and Research, Shirpur (2018-2019). Research Scholar, Institute of Chemical Technology, Mumbai (2022-Present). Assistant Professor, Dr. D Y Patil Institute of Pharmaceutical Science and Research, Pune (2019-2020, 2024). Expertise in preclinical drug studies, rodent surgery, data analysis, and project planning.

🏆Award and Honor

DAE-ICT Fellowship, 2024. 1st Position in Poster Presentation, 7th International Conference on “Emerging Trends in Drug Development and Delivery” (2024). Research Excellence Award, GEU, Dehradun (2015). Best Paper Presentation Award, TriboIndia 2023, NIT Srinagar

🔬 Research Focus

Dr. Patil’s research spans preclinical drug development, focusing on neurological disorders and cancer. His work investigates therapeutic targets, pharmacodynamics, and the molecular mechanisms of disease pathology. Key areas of interest include rodent models, drug efficacy, safety profiles, and mitochondrial toxicity. His publications highlight cancer cell cytotoxicity and cardioprotective effects, contributing to the understanding of pharmacological agents in disease treatment.

Publications Top Noted

1. Title: Cardioprotective effect of CB1 receptor antagonist AM251 against β receptor-stimulated myocardial infarction via modulation of NF-kB signaling pathway in diabetic mice

Year: 2024
Authors: Pawar, H.D., Patil, Y., Patil, A., Ojha, S., Goyal, S.N.
Citation: Heliyon, 10(15), e35138
Citations: 0

2. Title: Mitochondria-targeted derivative of pterostilbene, a dietary phytoestrogen, exhibits superior cancer cell cytotoxicity via mitochondrial superoxide mediated induction of autophagy

Year: 2023
Authors: Ibrahim, M.K., Nandha, S.R., Patil, A.S., Sharma, D., Sandur, S.K.
Citation: Advances in Redox Research, 8, 100071
Citations: 1

3. Title: Mitochondriotropic Derivative of Ethyl Ferulate, a Dietary Phenylpropanoid, Exhibits Enhanced Cytotoxicity in Cancer Cells via Mitochondrial Superoxide-Mediated Activation of JNK and AKT Signalling

Year: 2023
Authors: Patil, A.S., Ibrahim, M.K., Sathaye, S., Sharma, D., Sandur, S.K.
Citation: Applied Biochemistry and Biotechnology, 195(3), 2057–2076
Citations: 2

4. Title: Plant-derived natural therapeutics targeting cannabinoid receptors in metabolic syndrome and its complications: A review

Year: 2020
Authors: Patil, A.S., Mahajan, U.B., Agrawal, Y.O., Sharma, C., Goyal, S.N.
Citation: Biomedicine and Pharmacotherapy, 132, 110889
Citations: 17

5. Title: Protective effect of omeprazole and lansoprazole on β-receptor stimulated myocardial infarction in Wistar rats

Year: 2019
Authors: Patil, A.S., Singh, A.D., Mahajan, U.B., Ojha, S., Goyal, S.N.
Citation: Molecular and Cellular Biochemistry, 456(1-2), 105–113
Citations: 17

 

Jessica Abene| Oncology| Best Researcher Award

Posted on by ScienceFather

Ms. Jessica Abene| Oncology| Best Researcher Award

Ms. University of Pennsylvania,  United States

Jessica Abene is a dedicated nursing professional with a passion for advancing healthcare through evidence-based research. She earned her Bachelor of Nursing Science (BSN) from the University of Pennsylvania in 2023 and is currently pursuing a Master’s in Statistics and Data Science, as well as a PhD. Jessica is deeply engaged in research focused on improving patient care, particularly in oncology and eating disorders. She is an author of several publications, including systematic reviews on chemotherapy toxicities, food insecurity, and binge eating. Her expertise extends to clinical trials and the development of innovative healthcare solutions, such as a smart swaddle for infants with neonatal abstinence syndrome. Jessica is committed to improving patient quality of life through her work as a graduate research assistant and peer reviewer.

Profile

Scopus

🎓 Education

University of Pennsylvania Bachelor of Nursing Science (BSN), 2023. Master of Statistics and Data Science, In Process. Doctor of Philosophy, In Process

💼 Experience

Graduate Research Assistant, University of Pennsylvania, 2021-Present Jessica leads research on diet interventions to alleviate chemotherapy toxicities, coordinates data for clinical trials, and manages a systematic review on food insecurity and binge eating. Peer Reviewer, European Journal of Oncology Nursing, 2024-Present Evaluates submissions for scientific rigor, providing feedback to improve clarity and validity. Penn Nursing Innovation Accelerator Awardee, 2022 Led a team to develop a smart swaddle for infants with neonatal abstinence syndrome, offering comfort and distress relief.

🏆 Awards & Honors

Best Review Paper, International Journal of Eating Disorders (2023) Recognized for outstanding scholarly work as an early career scholar. Rita and Alex Hillman Foundation Pilot Award ($5,000) Awarded for innovative healthcare research. Doctoral Student Organization Research Grant ($325) Provided funding to support academic research. Penn Nursing Innovation Accelerator Awardee ($2,500) Awarded for leading an innovation team developing a smart swaddle system. Eastern Nursing Research Society Annual Conference Abstract Presentation (2023) Presented impactful research findings.

🔬 Research Focus

Jessica’s research aims to improve patient outcomes through evidence-based interventions. She is particularly focused on the impact of diet on chemotherapy toxicities and quality of life, as well as the relationship between food insecurity and binge eating disorders. Additionally, she coordinates clinical trials and studies exploring the effects of lymphedema and fibrosis treatment. Her innovative work includes developing a smart swaddle system for infants with neonatal abstinence syndrome (NAS). Jessica’s research seeks to create practical solutions for complex health challenges and contribute to enhancing patient care in diverse clinical settings.

🏆Conclusion 

Jessica Abene’s combination of rigorous academic training, innovative research, and leadership in healthcare makes her a standout candidate for the Best Researcher Award. Her systematic reviews, dedication to improving patient quality of life, and groundbreaking work in the intersection of healthcare and technology reflect her potential to make significant contributions to the nursing field. Continuing to expand her research network and engaging more broadly with the community will further enhance her already impressive career trajectory.

Publication

  • Dietary Interventions for Alleviating Chemotherapy Toxicities in Patients with Cancer: A Systematic Review
    Year: 2024
    Authors: Abene, J. & Deng, J.
    Status: In process

 

  • Diet as an Adjunct Therapy in Reducing Chemotherapy Toxicities and Improving Patients’ Quality of Life: A Systematic Review and Meta-Analysis
    Year: 2024
    Authors: Abene, J., Tyburski, S., Kral, T. V. E., Quinn, R., & Deng, J.
    Journal: Nutrition and Cancer, 1–19
    DOI: 10.1080/01635581.2024.2437833

 

  • Food Insecurity and Binge Eating: A Systematic Review and Meta-Analysis
    Year: 2023
    Authors: Abene, J. A., Tong, J., Minuk, J., Lindenfeldar, G., Chen, Y., & Chao, A. M.
    Journal: The International Journal of Eating Disorders, 56(7), 1301–1322

 

  • Binge Eating Disorder and Eating Self-Efficacy in Adults Seeking Bariatric Surgery
    Year: 2022
    Authors: Chao, A. M., Abene, J., Allison, K. C., Pearl, R. L., Wadden, T. A., Williams, N. N., & Tronieri, J. S.
    Journal: Clinical Obesity, e12531
    DOI: 10.1111/cob.12531

 

  • The Importance of Student Nursing and Engineering Collaborations
    Year: 2022 (May 20)
    Authors: Leary, M., Abene, J.
    Journal: American Nurse

 

Di Zhu| Immuno-oncology| Best Researcher Award

Posted on by ScienceFather

Mr. Di Zhu| Immuno-oncology| Best Researcher Award

Professor at Fudan University,  China

Di Zhu is a Professor in the Department of Pharmacology at Fudan University, specializing in immuno-oncology and cancer research. Born on October 13, 1983, he holds a Ph.D. in Biochemistry and Molecular Biology. With over 8 years of academic experience, he has pioneered groundbreaking therapies targeting colorectal cancer. Recognized globally for his contributions to cancer immunotherapy, he combines innovative research with clinical applications to improve patient outcomes.

Profile

Scholar

Education 🎓

Ph.D. in Biochemistry & Molecular Biology (2005–2010), Shanghai Institute of Biochemistry and Cell Biology, CAS. Postdoctoral Fellow (2011–2015), Dana-Farber Cancer Institute, Harvard University. Undergraduate studies at Shandong University, earning accolades like the National Sci. & Tech. Challenge Cup (2004).

Experience 💼

Researcher: Fudan University, School of Basic Medical Sciences (2021–Present). Researcher: Minhang & Zhongshan Hospitals, Fudan University (2017–Present). Researcher: Fudan University, School of Pharmacy (2016–2021). Led 12 projects, supervised 16 research scholars, and organized 5 workshops globally.

Awards and Honors 🏅

Gold Medal: Global Life & Health Technology Concept Validation (2024). Excellence Award: Hai Ju Ying Cai Global Innovation (2024). Outstanding Young Scientist: Shanghai Society of Biotechnology (2022). 1000 Talent Young Award: CPC Central Committee (2016). Multiple national and international recognitions for cancer research.

Research Focus 🔬

Therapies: Pioneered BCL9/β-catenin inhibitors for colorectal cancer. Immunotherapy: Enhanced T-cell responses and reduced immune resistance. Innovative Molecules: Developed selective inhibitors for challenging pathways. Publications: Authored impactful research in top journals, advancing cancer treatment.

Conclusion

Dr. Di Zhu exemplifies the qualities of a world-class researcher. His groundbreaking contributions to cancer therapy, robust academic output, and numerous accolades strongly support his nomination for the Best Researcher Award, affirming his leadership and innovation in the field of pharmacology and immuno-oncology.

Publication

 

  • Clinical cancer immunotherapy: Current progress and prospects
    Authors: C Liu, M Yang, D Zhang, M Chen, D Zhu
    Journal: Frontiers in Immunology 13, 961805
    Citations: 140 (2022)

 

  • Wnt signaling pathway in cancer immunotherapy
    Authors: Y Zhou, J Xu, H Luo, X Meng, M Chen, D Zhu
    Journal: Cancer Letters 525, 84-96
    Citations: 125 (2022)

 

  • IFNα potentiates anti–PD-1 efficacy by remodeling glucose metabolism in the hepatocellular carcinoma microenvironment
    Authors: B Hu et al., including D Zhu
    Journal: Cancer Discovery 12 (7), 1718-1741
    Citations: 123 (2022)

 

  • The Cyclophilin A–CD147 complex promotes the proliferation and homing of multiple myeloma cells
    Authors: DI Zhu et al.
    Journal: Nature Medicine 21 (6), 572-580
    Citations: 116 (2015)

 

  • Pharmacological inhibition of β-catenin/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating Treg cells
    Authors: M Feng et al., including D Zhu
    Journal: Science Advances 5 (5), eaau5240
    Citations: 100 (2019)

 

  • Cyclophilin A and CD147: Novel therapeutic targets for the treatment of COVID-19
    Authors: C Liu, A von Brunn, D Zhu
    Journal: Medicine in Drug Discovery 7, 100056
    Citations: 91 (2020)

 

  • T-cell-based immunotherapy in colorectal cancer
    Authors: M Feng, Z Zhao, M Yang, J Ji, D Zhu
    Journal: Cancer Letters 498, 201-209
    Citations: 67 (2021)

 

  • Targeting the tumor immune microenvironment for cancer therapy in human gastrointestinal malignancies
    Authors: Y Zhang et al., including D Zhu
    Journal: Cancer Letters 458, 123-135
    Citations: 55 (2019)

 

  • Targeting Cyclophilin A and CD147 to Inhibit Replication of SARS-CoV-2 and SARS-CoV-2-Induced Inflammation
    Authors: F Yang et al., including D Zhu
    Journal: Molecular Pharmacology
    Citations: 1 (2023)

 

  • New Approaches Targeting Immuno-oncology and Tumor Microenvironment
    Authors: D Zhu, F He
    Book Chapter: Cancer Treatment: An Interdisciplinary Approach, 63-90
    Citations: 1 (2022)

 

 

 

Angelika Długosz-Pokorska | cancer research | Women Researcher Award

Posted on by ScienceFather

 Dr. Angelika Długosz-Pokorska | cancer research |Women Researcher Award

 Dr at Medical University of Łódź,  Poland

A dedicated researcher and project leader at the Medical University of Lodz, Poland, with expertise in pharmacological characterization and anticancer drug development. As Principal Investigator and Co-investigator, led projects funded by prestigious grants like OPUS and SONATA, focusing on opioid peptide analogs and alpha-methylidene-delta-lactones. Supervising international student exchanges and engaging in expert activities, workshops, and editorial work. Recognized with numerous awards for scientific excellence, including Rector’s Awards and IF=8.638 for publication series on opioid mimetics and glutathione peroxidase. Committed to advancing medical science through innovative research and academic leadership.

Profile

  1. Scopus

 

  1. Orcid

📜 Employment History:

Research Associate (2017-present) Medical University of Lodz, Poland; Faculty of Medicine. Co-investigator (2016-2021)
Project: Rational design and pharmacological characterization of chimeric cyclic opioid peptide analogs targeting multiple receptors
Grant: OPUS 9, project ID 2015/17/B/ST5/00153. Principal Investigator (2016-2021) Project: Analysis of the anticancer activity of new synthetic alpha-methylidene-delta-lactones in selected cell lines Grant: SONATA, project ID 2015/17/D/NZ3/02226. Supervisor, Project Manager, and Principal Investigator (2018-present) Project: Analysis of the anticancer activity and molecular mechanism of action of new hybrid molecules containing uracil skeleton with an exo-cyclic methylene group Grant: PRELUDIUM13, project ID UMO-2017/25/N/NZ3/01039

📚 Short Research Training:

University of Rouen, France (2014) Laboratoire de Neuropsychopharmacologie Expérimentale

🌍 Activities:

  • Expert Activity/Reviewer (2024)
    Platform: Qeios
  • International Student Exchanges and ERASMUS Supervision (2024)
    Engaging in initiatives and participating in European Union programs, overseeing ERASMUS students.
  • Participation in Scientific Workshops and Research Teams (2024)
    Engaging in workshops aimed at exchanging experiences, self-improvement, and organization.
  • Editorial Work (2023-present)
    Journal: Reviewer for Breast Cancer-Tokyo, ISSN 1340-6868, eISSN 1880-4233.

🏆 Awards and Distinctions:

2022: First-level Special Award for Outstanding Didactic Work by Academic Teachers Medical University of Lodz.

2020: Team Distinction from the Faculty of Chemistry Nicolaus Copernicus University in Toruń Rector’s Award Medical University of Lodz Second-degree scientific award for a series of publications titled: ‘Investigation of the Anticancer Properties of Synthetic Analogues of Compounds Isolated from Plants’. (Impact Factor – 8.034). Polish Intelligent Development Award – Nomination.

2019: Investigation of Anticancer Activity of Synthetic Analogues of Methylenolactones”, IF=4.026PTBioch Bursary Scholarship 44th FEBS Congress “From Molecules to Living Systems”. Rector’s Award Medical University of Lodz Second Prize for Publication: ‘Synthetic Analogues of Coumarin as Novel Agents with Anticancer Activity’. (Impact Factor = 4.173). Rector’s Award Medical University of Lodz Team Second award for Publication Series:

2017: Rector’s Award Medical University of Lodz First Prize for Publication Series: “Synthesis and Investigation of Biological Activity of Opioid Mimetics and Glutathione Peroxidase”. (IF=8.638). Rector’s Award Medical University of Lodz Team First Prize for Publication Series: “Anticancer Properties of Novel Synthetic Dicoumarins”. (IF=6.221) “Investigation of Anticancer Activity of Sesquiterpene Lactones”. (IF=4.994)

2016: Rector’s Award Medical University of Lodz First Prize for Publication Series: “Anticancer Properties of Novel Synthetic Lactones in Combination with Known Anticancer Drugs”. (IF = 8.835)

Publications Top Notes 📝

  • Title: Synthesis of New Chiral β-Carbonyl Selenides with Antioxidant and Anticancer Activity Evaluation-Part I
    • Authors: Laskowska, A., Pacuła-Miszewska, A.J., Obieziurska-Fabisiak, M., et al.
    • Journal: Materials
    • Year: 2024
    • Volume: 17
    • Pages: 1–15
    • Summary: This study focuses on the synthesis of new chiral β-carbonyl selenides and evaluates their antioxidant and anticancer activities, providing valuable insights into potential therapeutic agents.

 

  • Title: New Uracil Analog with Exocyclic Methylidene Group Can Reverse Resistance to Taxol in MCF7 Cancer Cells
    • Authors: Długosz-Pokorska, A., Perlikowska, R., Janecki, T., et al.
    • Journal: Biologics: Targets and Therapy
    • Year: 2023
    • Volume: 17
    • Pages: 69–83
    • Summary: This article presents a novel uracil analog with potential to reverse resistance to Taxol in MCF7 cancer cells, indicating its promising role as an anticancer agent.

 

  • Title: New Uracil Analog- U-359 can Reverse Resistance to Taxol in MCF-7 cancer cells
    • Authors: Długosz-Pokorska, A., Perlikowska, R., Janecki, T., et al.
    • Journal: Acta Biochimica Polonica
    • Year: 2023
    • Volume: 70
    • Pages: 56
    • Summary: This study explores another uracil analog’s potential to reverse resistance to Taxol in MCF-7 cancer cells, indicating a promising avenue for further research.

 

  • Title: The Influence of Long Carbon Chains on the Antioxidant and Anticancer Properties of N-Substituted Benzisoselenazolones and Corresponding Diselenides
    • Authors: Pacuła-Miszewska, A.J., Obieziurska-Fabisiak, M., Jastrzębska, A., et al.
    • Journal: Pharmaceuticals
    • Year: 2023
    • Volume: 16
    • Pages: 1–11
    • Summary: This research investigates the impact of long carbon chains on the antioxidant and anticancer properties of N-substituted benzisoselenazolones and corresponding diselenides, providing valuable insights into structure-activity relationships.

 

  • Title: Attachment of Chiral Functional Groups to Modify the Activity of New GPx Mimetics
    • Authors: Laskowska, A., Pacuła-Miszewska, A., Długosz-Pokorska, A., et al.
    • Journal: Materials
    • Year: 2022
    • Volume: 16
    • Pages: 1–14
    • Summary: This study explores the modification of GPx mimetics’ activity through the attachment of chiral functional groups, offering potential strategies for enhancing therapeutic effects.

 

Mohammad Khosravi | Immunotherapy | Excellence in Innovation

Posted on by ScienceFather

Assoc Prof Dr. Mohammad Khosravi | Immunotherapy | Excellence in Innovation

Assoc Prof Dr. Shahid Chamran University of Ahvaz Iran

👩‍🔬 A highly skilled immunologist and veterinarian with a Ph.D. from Tehran University, specializing in molecular characterization and immunology techniques. Experienced in cell culture, gene characterization, protein analysis, and chromatography. Proficient in serology techniques, immunization, and animal handling. Skilled in bioinformatics analysis and extensive knowledge of SPSS and Microsoft Office Suite. Adept at teaching fundamental and advanced immunology to both D.V.M. and Ph.D. students. Demonstrated expertise in avian immunology and diagnostic techniques. Accomplished in research and teaching, contributing significantly to the field of immunology and veterinary medicine.🌟

 

Profile

Scopus

 

Education 📚

PhD in Immunology: Tehran University, Tehran, Iran, 2013.Thesis: Molecular characterization of chicken class II transactivator gene.DVM (Doctor of Veterinary Medicine): Shahrekord University, Chaharmahal bakhteyari, Iran, 2007.Thesis: A comparison of ELISA and histopathology for the detection of paratuberculosis in dairy cattle.

Research Experience and Technical Skills 🔬

Cell culture (primary and immortalized cell lines).Stem cell isolation technique.Isolation of leukocyte subsets.Purification of antibody subsets.Gene characterization: PCR, RT-PCR, QRT-PCR, Real Time-PCR, Gene cloning, Bioinformatics analysis.Protein and Oligosaccharide SDS-PAGE.Western blotting.Serology techniques: ELISA, Agglutination, Precipitation, Hemagglutination.Chromatographic techniques: Affinity, Ion-exchange, Gel-filtration.Purification of protein and carbohydrate.Immunization techniques.Animal handling.Extensive experience of SPSS, Microsoft Word, Excel, PowerPoint.Hapten immunization (Preparation of the hyper immune sera against drugs and metals).Synthesis of the metal nanoparticles (Fe, Cu, Au, Zn).Synthesis of the immunomagnetic beads for separation of the microorganisms, cells, drugs, and metals.Synthesis of the latex agglutination beads for detection of the cells, drugs, and metals.

Teaching Experience (2013-2022) 📖

At Shahid Chamran University of Ahvaz, Khuzestan, Iran:

  • Fundamental Immunology for D.V.M students.
  • Advanced Immunology for Ph.D students of bacteriology.
  • Serology Technique for D.V.M students.
  • Avian Immunology for PhD students of poultry hygiene and diseases.
  • Diagnostic Immunology for Ph.D students of clinical pathology.

Publications Top Notes 📝

  1. Title: Quorum quenching probiotics modulated digestive enzymes activity, growth performance, gut microflora, haemato-biochemical parameters and resistance against Vibrio harveyi
    • Authors: R Ghanei-Motlagh, T Mohammadian, D Gharibi, M Khosravi, E Mahmoudi, …
    • Journal: Aquaculture
    • Volume: 531
    • Pages: 735874
    • Year: 2021

 

  1. Title: Quorum Quenching Properties and Probiotic Potentials of Intestinal Associated Bacteria in Asian Sea Bass Lates calcarifer
    • Authors: R Ghanei-Motlagh, T Mohammadian, D Gharibi, S Menanteau-Ledouble, …
    • Journal: Marine drugs
    • Volume: 18
    • Issue: 1
    • Pages: 23
    • Year: 2019

 

  1. Title: Feed supplementation with quorum quenching probiotics with anti-virulence potential improved innate immune responses, antioxidant capacity and disease resistance in Asian …
    • Authors: R Ghanei-Motlagh, D Gharibi, T Mohammadian, M Khosravi, E Mahmoudi, …
    • Journal: Aquaculture
    • Volume: 535
    • Pages: 736345
    • Year: 2021

 

  1. Title: Antibacterial effects of Aloe vera extracts on some human and animal bacterial pathogens
    • Authors: D Gharibi, M Khosravi, Z Hosseini, F Boroun, SK Barzgar, A Forughi Far
    • Journal: Journal of Medical Microbiology and Infectious Diseases
    • Volume: 3
    • Issue: 1
    • Pages: 6-10
    • Year: 2015